Retatrutide vs Ozempic Ended in Double the Weight Loss

Ozempic has spent three years as the name everyone knows in blood sugar and weight loss. Last week, a drug that could take its place at the top of the conversation posted results that made the industry sit up.

Eli Lilly announced on October 28 that its experimental drug retatrutide beat Novo Nordisk's Ozempic on both blood sugar control and weight loss in a late-stage trial of adults with type 2 diabetes, Reuters reported. People on the highest dose of retatrutide lost an average of 20.9 per cent of their body weight over 80 weeks, more than double the 9.4 per cent lost on the highest approved dose of Ozempic. The results are the company's own topline numbers, so the company still has to publish the full data for other scientists to examine, and no regulator has approved the drug yet. This is what the retatrutide vs Ozempic matchup does and does not change for Canadians.

Key takeaways

In an 80-week trial of nearly 1,300 adults, the 12 mg dose of retatrutide produced 20.9 per cent average weight loss, compared with 9.4 per cent on Ozempic 2 mg.

Both retatrutide doses lowered A1C, a measure of average blood sugar, by 2.2 percentage points, compared with 1.8 points for Ozempic.

About 7.9 per cent of people on the highest retatrutide dose stopped because of side effects, compared with 2.7 per cent on Ozempic.

Retatrutide is experimental, and neither Health Canada nor any other regulator has approved it.

Roughly three million Canadian adults already take a GLP-1 medication, according to a 2026 Leger survey.

What did the head-to-head trial find?

The head-to-head trial, called TRANSCEND-T2D-2, enrolled 1,298 adults whose type 2 diabetes was not well controlled on metformin, with or without one other common medication, according to Fierce Biotech. Participants took a weekly injection of retatrutide at 9 mg or 12 mg, or Ozempic at 2 mg, its highest approved dose for diabetes, and everyone knew which drug they were on.

After 80 weeks, both retatrutide doses lowered A1C, the standard measure of average blood sugar over the previous few months, by 2.2 percentage points, against 1.8 points for Ozempic. Weight fell by 19.5 per cent on the 9 mg dose and 20.9 per cent on 12 mg, compared with 9.4 per cent on Ozempic. Those figures estimate what would have happened had everyone stayed on their assigned drug for the full 80 weeks, so results in everyday use may differ.

How does a triple agonist work?

Ozempic belongs to a class of drugs that mimic one gut hormone, GLP-1, which helps control blood sugar and appetite. Retatrutide acts on three hormone pathways at once, GLP-1, GIP, and glucagon, which is why researchers call it a triple agonist, a drug that switches on three receptors instead of one.

The idea is that pulling three levers produces bigger effects on blood sugar, appetite, and weight, and this trial suggests that theory holds up in people. Lilly also reported larger improvements in some heart risk factors, though the company has not released those details in full. Our explainer on how weight loss drugs work beyond willpower covers the basics of this whole drug family.

Which side effects came with the bigger results?

The retatrutide vs Ozempic results came with a trade-off for the stronger drug. About 7.9 per cent of people on the highest retatrutide dose stopped treatment because of side effects, compared with 4.8 per cent on the lower dose and 2.7 per cent on Ozempic. The most common problems were stomach-related, such as nausea, vomiting, and diarrhea.

Novo Nordisk told Reuters that Ozempic should not be judged on weight loss alone, noting that the drug has shown benefits for the heart, kidneys, and liver. It is also worth remembering that the company that makes retatrutide funded and announced the trial. Eating much less can also make it harder to get enough protein, which is why our guide to whether you are eating enough protein is worth a look for anyone on these drugs.

When could Health Canada approve it?

Nothing changes at your pharmacy this month. Lilly plans to file for approval in the United States early in 2027. Retatrutide would still need its own review by Health Canada before any Canadian could get a prescription, and Lilly has not said when it plans to file here. Our story on what Health Canada's generic Wegovy approval means shows how that review step plays out. Anything sold online as retatrutide today is not an approved product, since Lilly says the drug cannot legally be sold for human use, and our report on Health Canada shutting down a peptide seller explains the risks.

Demand for this class of drugs is already enormous in Canada. A Leger survey reported by The Canadian Press estimated that about three million Canadian adults were taking a GLP-1 medication early in 2026, with another two million interested. Heart & Stroke reports that more than 3.9 million Canadians live with diabetes. Our story on why people on GLP-1 drugs are moving less is a reminder that the medicine works best alongside daily habits.

What should you do about your blood sugar now?

With November marking Diabetes Awareness Month in Canada, the foundation of good blood sugar care has not changed, whatever the next drug turns out to be. Knowing your numbers, moving regularly, eating well, and working with a provider who can adjust treatment as options improve still do most of the work.

Do not switch or stop anything because of a headline. Any change to a diabetes medicine belongs in a conversation with your prescriber.

Know your A1C. Ask for your most recent result and the target your doctor has in mind for you.

Ask about today's options. Several effective medicines now exist that were not available five years ago, so a review can be worthwhile.

Check your coverage. Ask your pharmacist what your provincial plan or private insurance covers before you pay out of pocket.

Get tested if you never have. A simple blood test can show whether your blood sugar is creeping up, as our guide to finding out where your blood sugar stands explains.

Frequently asked questions

Is retatrutide available in Canada?

Retatrutide is experimental, and neither Health Canada nor any other regulator has approved it. Lilly plans to seek approval in the United States in early 2027, and a Canadian review would follow its own timeline. Products sold online as retatrutide are unapproved and carry real safety risks, so avoid them.

How is retatrutide different from Ozempic?

Ozempic mimics one gut hormone, GLP-1, while retatrutide acts on three, GLP-1, GIP, and glucagon. In the first trial of retatrutide vs Ozempic, retatrutide lowered blood sugar more and produced roughly twice the weight loss, though more people stopped it because of side effects. Lilly has not yet published the full results.

Should you change medications because of this trial?

A single trial of an unapproved drug is no reason to stop or switch your current treatment. If your blood sugar or weight is not where you and your care team want it, ask about the approved options available today. Your doctor or pharmacist can review your medicines, your coverage, and your goals.

Your next step

If it has been a while since anyone reviewed your blood sugar or your treatment plan, this is a good month to start that conversation. The Medimap Health Hub has more on weight and everyday health, and you can find a family doctor near you and book an appointment this week.

Disclaimer: This article is for general information only and is not medical advice. It does not replace a conversation with a doctor or other qualified health professional who knows your history. If you think you are having a medical emergency, call 911 or go to the nearest emergency department.